U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H18ClFN4O2
Molecular Weight 448.877
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALLITINIB

SMILES

FC1=CC(COC2=CC=C(NC3=C4C=C(NC(=O)C=C)C=CC4=NC=N3)C=C2Cl)=CC=C1

InChI

InChIKey=MVZGYPSXNDCANY-UHFFFAOYSA-N
InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)

HIDE SMILES / InChI
Molecular Formula C24H18ClFN4O2
Molecular Weight 448.877
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/24612546 | http://adisinsight.springer.com/drugs/800032292

AST-1306, also known as Allitinib, is an orally active potent, selective, irreversible inhibitor of the HER family of receptor tyrosine kinases. AST-1306 inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems. AST1306 potently suppressed tumor growth in ErbB2-overexpressing adenocarcinoma xenograft and FVB-2/N(neu) transgenic breast cancer mouse models. Allitinib is in Phase I clinical trial for the treatment of advanced solid tumors. Serious adverse effects detected were: diarrhea, dehydration and hyperbilirubinemia.

Originator

Allist Pharmaceuticals
1
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/21789172

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.5 nM [IC50]
Inhibitor
8297
 3.0 nM [IC50]
Inhibitor
8297
 0.8 nM [IC50]
Substrate
661
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
428
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
2014 Aug 1
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.
2014 Sep 29
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
2016 Jun
Patents

Patents

US20140121126 A1
1
US20160002600 A1
1
WO2016191471 A1
1

Sample Use Guides

In Vivo Use Guide
1000 mg three times daily
Route of Administration: Oral
In Vitro Use Guide
The Calu-3 lung adenocarcinoma and BT474 breast cancer cell line, containing high levels of ErbB2, were more sensitive to AST1306, with IC50 values of 0.23 and 0.97 uM/L, respectively.
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:55:03 GMT 2023
Edited
by admin
on Sat Dec 16 15:55:03 GMT 2023
Record UNII
CX0M5RO7CY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALLITINIB
Common Name English
AST1306
Common Name English
N-(4-((3-CHLORO-4-((3-FLUOROBENZYL)OXY)PHENYL)AMINO)QUINAZOLIN-6-YL)ACRYLAMIDE
Systematic Name English
ALS 1306
Common Name English
AST 1306
Common Name English
2-PROPENAMIDE, N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-
Systematic Name English
N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2-PROPENAMIDE
Systematic Name English
Code System Code Type Description
FDA UNII
CX0M5RO7CY
Created by admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
PRIMARY
PUBCHEM
24739943
Created by admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID30647124
Created by admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
PRIMARY
NCI_THESAURUS
C179280
Created by admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
PRIMARY
CAS
897383-62-9
Created by admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
PRIMARY
Related Record Type Details
EPIDERMAL GROWTH FACTOR RECEPTOR
TARGET -> INHIBITOR
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
TARGET -> INHIBITOR
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
Structure of ALLITINIB
EXCRETED UNCHANGED
FECAL
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
Structure of N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of N-(4-(3-CHLORO-4-HYDROXY-ANILINO)QUINAZOLIN-6-YL)PROPANAMIDE
METABOLITE -> PARENT
FECAL; PLASMA
Structure of N-(4-((3-CHLORO-4-HYDROXYPHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of L-CYSTEINE, N-ACETYL-S-(3-((4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)AMINO)-3-OXOPROPYL)-
METABOLITE -> PARENT
URINE
Structure of (2S,3S,4S,5R,6S)-6-(6-AMINO-4-(3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)ANILINO)QUINAZOLIN-2-YL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
METABOLITE -> PARENT
PLASMA
Structure of (2R)-2-ACETAMIDO-3-(3-((4-(3-CHLORO-4-HYDROXY-ANILINO)QUINAZOLIN-6-YL)AMINO)-3-OXO-PROPYL)SULFANYL-PROPANOIC ACID
METABOLITE -> PARENT
FECAL
Structure of 6-AMINO-4-(3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)ANILINO)QUINAZOLIN-2-OL
METABOLITE -> PARENT
Structure of (2R)-2-AMINO-3-(3-((4-(3-CHLORO-4-HYDROXY-ANILINO)QUINAZOLIN-6-YL)AMINO)-3-OXO-PROPYL)SULFANYL-PROPANOIC ACID
METABOLITE -> PARENT
FECAL; URINE
Structure of N-(4-(3-CHLORO-4-HYDROXY-ANILINO)-2-HYDROXY-QUINAZOLIN-6-YL)PROP-2-ENAMIDE
METABOLITE -> PARENT
FECAL; URINE
Structure of 2-PROPENAMIDE, N-(4-((3-CHLORO-4-HYDROXYPHENYL)AMINO)-6-QUINAZOLINYL)-
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of (2-CHLORO-4-((2-HYDROXY-6-(PROP-2-ENOYLAMINO)QUINAZOLIN-4-YL)AMINO)PHENYL) HYDROGEN SULFATE
METABOLITE -> PARENT
URINE
Structure of N-(4-(3-CHLORO-4-HYDROXY-ANILINO)QUINAZOLIN-6-YL)-3-HYDROXY-PROPANAMIDE
METABOLITE -> PARENT
FECAL
Structure of 4,6-QUINAZOLINEDIAMINE, N4-(3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)-
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC AT DAY 1

IN CANCER PATIENTS

THREE TIMES A DAY

ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC IN CANCER PATIENTS

AT DAY 24

THREE TIMES A DAY FOR 21 DAYS

ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC THREE TIMES A DAY

IN CANCER PATIENTS

AT DAY 1

ORAL ADMINISTRATION

Tmax PHARMACOKINETIC IN CANCER PATIENTS

AT DAY 24

THREE TIMES A DAY FOR 21 DAYS

ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966